全文获取类型
收费全文 | 8819篇 |
免费 | 748篇 |
国内免费 | 343篇 |
专业分类
耳鼻咽喉 | 24篇 |
儿科学 | 82篇 |
妇产科学 | 74篇 |
基础医学 | 647篇 |
口腔科学 | 370篇 |
临床医学 | 1255篇 |
内科学 | 1221篇 |
皮肤病学 | 136篇 |
神经病学 | 256篇 |
特种医学 | 683篇 |
外科学 | 450篇 |
综合类 | 1112篇 |
现状与发展 | 1篇 |
预防医学 | 650篇 |
眼科学 | 99篇 |
药学 | 2156篇 |
4篇 | |
中国医学 | 259篇 |
肿瘤学 | 431篇 |
出版年
2024年 | 22篇 |
2023年 | 116篇 |
2022年 | 233篇 |
2021年 | 337篇 |
2020年 | 263篇 |
2019年 | 238篇 |
2018年 | 240篇 |
2017年 | 277篇 |
2016年 | 301篇 |
2015年 | 355篇 |
2014年 | 633篇 |
2013年 | 698篇 |
2012年 | 578篇 |
2011年 | 579篇 |
2010年 | 429篇 |
2009年 | 425篇 |
2008年 | 417篇 |
2007年 | 436篇 |
2006年 | 446篇 |
2005年 | 303篇 |
2004年 | 264篇 |
2003年 | 274篇 |
2002年 | 237篇 |
2001年 | 191篇 |
2000年 | 140篇 |
1999年 | 168篇 |
1998年 | 158篇 |
1997年 | 165篇 |
1996年 | 116篇 |
1995年 | 95篇 |
1994年 | 104篇 |
1993年 | 83篇 |
1992年 | 84篇 |
1991年 | 64篇 |
1990年 | 59篇 |
1989年 | 62篇 |
1988年 | 52篇 |
1987年 | 46篇 |
1986年 | 39篇 |
1985年 | 45篇 |
1984年 | 24篇 |
1983年 | 14篇 |
1982年 | 28篇 |
1981年 | 16篇 |
1980年 | 12篇 |
1979年 | 7篇 |
1978年 | 11篇 |
1977年 | 12篇 |
1976年 | 8篇 |
1973年 | 3篇 |
排序方式: 共有9910条查询结果,搜索用时 0 毫秒
1.
《Revista de gastroenterologia de Mexico》2022,87(1):52-58
IntroductionThe sofosbuvir-velpatasvir (SOF/VEL) combination is a direct-acting antiviral therapy that is authorized and available in Mexico, making the performance of a real-world multicenter study that evaluates the sustained virologic response at 12 weeks post-treatment a relevant undertaking.MethodsA retrospective review of the case records of 241 patients seen at 20 hospitals in Mexico was conducted to assess hepatitis C treatment with the SOF/VEL combination (n = 231) and the sofosbuvir/velpatasvir/ribavirin (SOF/VEL/RBV) combination (n = 10). The primary efficacy endpoint was the percentage of patients that achieved SVR at 12 weeks after the end of treatment.ResultsOverall SVR was 98.8% (95% CI 97.35-100%). Only three patients did not achieve SVR, two of whom had cirrhosis and a history of previous treatment with peg-IFN. Of the subgroups analyzed, all the patients with HIV coinfection, three patients with genotype 3, and the patients treated with the SOF/VEL/RBV combination achieved SVR. The subgroups with the lower success rates were patients that were treatment-experienced (96.8%) and patients with F1 fibrosis (95.5%). The most frequent adverse events were fatigue, headache, and insomnia. No serious adverse events were reported.ConclusionTreatments with SOF/VEL and SOF/VEL/RBV were highly safe and effective, results coinciding with those of other international real-world studies. 相似文献
2.
2015年中华医学会感染病学分会艾滋病学组发布了第三版《艾滋病诊疗指南》。新版指南强调抗病毒治疗时点前移:一旦成人确诊感染人类免疫缺陷病毒(HIV), 若无禁忌宜尽早启动抗HIV治疗。对于合并机会性感染的HIV感染者, 在感染控制、病情稳定后也应及早开始抗病毒治疗。尤其强调HIV合并结核患者在CD4阳性淋巴细胞数少于200/μL的情况下, 建议抗结核两周内即开始抗病毒治疗。在抗HIV治疗用药中, 淘汰了一些毒副作用大、依从性较差的药物, 如司他夫定、去羟肌苷、茚地那韦等, 优选抗病毒效力强、服药方便的组合, 如拉米夫定、替诺福韦、依非韦伦组合。对于HIV感染的婴幼儿, 亦主张及早抗HIV治疗。对于五岁以内的幼儿, 主张确诊后即启动抗病毒治疗。对于HIV感染的孕产妇, 建议尽快予以全程、联合抗HIV治疗, 寓防于治。 相似文献
3.
《Saudi Pharmaceutical Journal》2020,28(10):1243-1252
The novel coronavirus outbreak has reported to be rapidly spreading across the countries and becomes a foremost community health alarm. At present, no vaccine or specific drug is on hand for the treatment of this infectious disease. This review investigates the drugs, which are being evaluated and found to be effective against nCOVID-19 infection. A thorough literature search was performedon the recently published research papers in between January 2020 to May 2020, through various databases like “Science Direct”, “Google Scholar”, “PubMed”,“Medline”, “Web of Science”, and “World Health Organization (WHO)”. We reviewed and documented the information related with the current and future aspects for the management and cure of COVID-19. As of 21st July 2020 a total of 14,562,550 confirmed cases of coronavirus and 607,781 deaths have been reported world-wide. The main clinical feature of COVID-19 ranges from asymptomatic disease to mild lower respiratory tract illness to severe pneumonia, acute lung injury, acute respiratory distress syndrome (ARDS), multiple organ dysfunction, and death. The drugs at present used in COVID-19 patients and ongoing clinical trials focusing on drug repurposing of various therapeutic classes of drug e.g. antiviral, anti-inflammatory and/or immunomodulatory drugs along with adjuvant/supportive care. Many drugs on clinical trials shows effective results on preliminary scale and now used currently in patients. Adjuvant/supportive care therapy are used in patients to get the best results in order to minimize the short and long-term complications. However, further studies and clinical trials are needed on large scale of population to reach any firm conclusion in terms of its efficacy and safety. 相似文献
4.
The antiproliferative, cytotoxic and apoptogenic activities of Bufo melanostictus (Indian common toad) skin extract (TSE) on U937 and K562 leukemic cell line has been investigated. TSE significantly (P<0.001) reduced the time-dependent cell proliferation and decreased MTT values in U937 and K562 cells. TSE (IC50 doses) suppressed the proliferating cell nuclear antigen expression in both the cells. It was demonstrated that, TSE (IC50 doses) primarily arrested the U937 and K562 cells at G1 phase of the cell cycle. Confocal microscopy showed the altered fragmented nuclei and apoptotic bodies formation in TSE (IC50 doses) treated U937 and K562 cells. Membrane blebbing, cell surface shrinkage and perforation were observed through scanning electron microscope. TSE-induced DNA fragmentation in U937 and K562 cells was reflected in single-cell gel electrophoresis. TSE significantly (P<0.001) increase the length-width ratio of DNA mass as compared to control in comet assay. The flow cytometric analysis of annexin-V binding to the cancer cells further supported the apoptotogenic activity of TSE. The effect of TSE on normal human peripheral blood mononuclear cells viability and cytotoxicity was studied in culture and found to be less cytotoxic than on the U937 and K562 cells. The findings from the present study suggested that TSE might possess potent antineoplastic agent having antiproliferative, cytotoxic and apoptogenic activity against U937 and K562 myeloid leukemic cells. 相似文献
5.
本实验制作不同程度心肌缺血的动物模型,以声处理5%人血白蛋白为超声造影剂进行心肌灌注造影,探讨MCE时间-强度曲线各指标与心肌缺血程度间的关系。结果表明:心肌显影的峰值强度和曲线下面积均与缺血程度呈显著负相关(相关系数分别为r=-0.98,P值<0.005;r=-0.94,P值<0.05),且能区分轻度、中度和重度三种程度的心肌缺血;而三项时间指标与心肌缺血程度间未发现显著性差异。本实验的初步结果表明,MCE是一项活体评估局部心肌血流灌注的有效方法。 相似文献
6.
膨润土对药用混悬液助悬性能的考察 总被引:9,自引:1,他引:8
本文报道了无机胶体膨润土(Bentonite)作为助悬剂在炉甘石洗剂中的应用,并与有机助悬剂及另一种无机胶体XVT—M进行比较,显示了其优异的助悬性能。 相似文献
7.
改善胰岛素敏感性对血压影响的相关研究 总被引:3,自引:0,他引:3
目的 :观察胰岛素增敏剂二甲双胍改善 2型糖尿病胰岛素敏感性后对血压的影响。方法 :71例 2型糖尿病人口服二甲双胍 (格华止 ) 85 0 mg,qd-bid。治疗前后测定 BMI、血压、FBG、PBG、FINS、PINS,并按 HOMA模型计算胰岛素抵抗指数和胰岛素分泌指数。结果 :( 1)二甲双胍治疗 8周后 ,BMI治疗前后无显著性差异 ;血压治疗后明显下降 ,降压幅度达 ( 13.1± 4.97) /( 4 .2 2± 9.93) mm Hg,血压治疗前后有显著性差异。 ( 2 )治疗后 F BG、 PBG、 FINS均明显下降 ,治疗前后有显著性差异。 ( 3)治疗后 HOMA-IR下降 ,IAI升高 ,治疗前后有显著性差异 ,但 HOMA-IS、 FINS/FBG无显著性差异。结论 :二甲双胍治疗 2型糖尿病 ,在降低血糖、改善 IR的同时 ,伴有血压的明显下降 相似文献
8.
实验性自身免疫性脑脊髓炎巨噬细胞活性MR成像的研究进展 总被引:2,自引:0,他引:2
MR成像是监测多发性硬化(MS)病情及其演变、评价疗效的重要手段,实验性自身免疫性脑脊髓炎(EAE)是公认的研究人类多发性硬化的动物模型。常规MR扫描仅能分析MS和EAE炎症反应的继发性改变。巨噬细胞是MS和EAE炎症反应中重要的效应细胞,超微超顺磁性氧化铁(USPIO)粒子能被巨噬细胞摄取,MR成像能显示MS和EAE病灶内吞噬了USPIO的巨噬细胞,分析其炎症反应自身的信息,是动态观察巨噬细胞浸润过程、进一步探索MS免疫病理机制的有效手段。本文综述超微超顺磁性对比剂的特性及其MR成像在EAE和MS病理机制方面的研究进展,评价其发展前景。 相似文献
9.
胆道消融剂在选择性胆道消融栓塞中的选用 总被引:4,自引:0,他引:4
目的 观察不同胆道消融剂选择性胆道消融栓寒对肝脏结构和功能的影响。方法无水乙醇、醋酸、盐酸、氧氧化钠分别消融姐道,OB胶栓塞巴马小型猪左外叶胆管,观察术后肝功及病理变化。结果术后各组肝功能各项指标除白蛋白外.均出现一过性增高,术后两周内恢复正常。尤水乙醇肝功变化没有其他组显著。其它各组坏死范围较无水乙醇大。其中氢氧化钠出现急性肝坏死,醋酸坏死范围大于左外叶。光镜下左外叶汇管区纤维明显增生,肝细胞数目减少。假小叶形成。Masson染色提示胶原纤维显著增生。结论无水乙醇与OB胶联合使用.行选择性胆道消融栓塞能使消融栓塞胆道引流区域肝组织萎缩纤维化,肝内假小叶形成。而且对机体影响最小,是目前安全的胆道消融剂。 相似文献
10.
Brian Wm. Davies M.D. Gary A. Pennington M.D. Bahman Guyuron M.D. 《Aesthetic plastic surgery》1993,17(2):125-128
Ambulatory surgery has become routine for many plastic surgery procedures. Anesthesia techniques including general anesthesia by inhalation and intravenous infusion and the dissociative technique have all been used successfully for outpatient anesthesia. Propofol (Diprivan), a relatively new agent, has proven to be a safe and effective general anesthesia agent for outpatient surgery. We report on our experience with propofol as an induction agent and continuous drip for general anesthesia maintenance in 100 consecutive outpatient, plastic surgery procedures performed in an office facility. Assessment factors were recovery-room time, nausea and vomiting in the recovery room and at home, hallucinations, patients' recollection of anesthesia experience, and overall patient satisfaction. 相似文献